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Impaired endothelial nitric oxide synthase (eNOS) activity
may be involved in the pathogenesis of diabetic
nephropathy. To test this, we used the type 2 diabetic db/db
mouse (BKS background) model and found impaired eNOS
dimerization and phosphorylation along with moderate
glomerular mesangial expansion and increased glomerular
basement membrane (GBM) thickness at 34 weeks of age.
Cultured murine glomerular endothelial cells exposed to high
glucose had similar alterations in eNOS dimerization and
phosphorylation. Treatment with sepiapterin, a stable
precursor of the eNOS cofactor tetrahydrobiopterin, or the
nitric oxide precursor L-arginine corrected changes in eNOS
dimerization and phosphorylation, corrected permeability
defects, and reduced apoptosis. Sepiapterin or L-arginine,
administered to db/db mice from weeks 26 to 34, did not
significantly alter hyperfiltration or affect mesangial
expansion, but reduced albuminuria and GBM thickness, and
decreased urinary isoprostane and nitrotyrosine excretion
(markers of oxidative stress). Although there was no change
in glomerular eNOS monomer expression, both sepiapterin
and L-arginine partially reversed the defect in eNOS
dimerization and phosphorylation. Hence, our results
support an important role for eNOS dysfunction in diabetes
and suggest that sepiapterin supplementation might have
therapeutic potential in diabetic nephropathy.
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Multiple mechanisms contribute to the development of
diabetic nephropathy, and there is increasing evidence that all
three types of glomerular cells are potential targets for
injury.1 Specifically, there is increasing evidence that
dysfunction of the fenestrated glomerular endothelial cells
(GEnCs) is an important contributory factor to progressive
diabetic glomerular injury.2–5 Nitric oxide (NO) is an
important endothelium-derived mediator, with multiple
actions, including vasodilation and antiplatelet, antiproli-
ferative, antiadhesive, permeability-decreasing, and anti-
inflammatory properties.3 Previous studies have examined
whether there are alterations in NO production and/or
bioavailability in diabetes but have provided conflicting
results. In vitro studies have shown that high glucose (HG)
medium could either induce4,5 or inhibit6 endothelial nitric
oxide synthase (eNOS) expression in cultured endothelial
cells. In animal model of diabetes mellitus, eNOS gene
expression has been described to be either unchanged,7
diminished,8,9 or increased.10,11 Hohenstein et al.12 recently
reported upregulated eNOS expression in glomeruli from
type 2 diabetic patients with nephropathy. In contrast, we
and others have found that eNOS insufficiency will accelerate
nephropathy in mouse models of both type 1 and type 2
diabetes.13–19 Therefore, the underlying mechanisms and
potential roles of impaired eNOS in glomerular endothelium
during the development of diabetic nephropathy still remain
incompletely understood.14
RESULTS
HG induced GEnC impairment and eNOS dysfunction
Pilot studies indicated that incubation of cultured mouse
GEnCs with HG for 48 h demonstrated significant alterations.
At that time, GEnCs in HG increased bovine serum albumin
(BSA) clearance compared with normal glucose (NG) medium
or mannitol (9.9±0.6% in NG and 11.0±1.0% in mannitol vs.
40.8±1.7% in HG after 40min, n¼ 5, Po0.05) (Figure 1a)
without significantly altering proliferation (data not shown).
In addition, HG induced profound apoptosis in GEnCs
(1±0.2% in NG vs. 7.9±0.4% in HG, n¼ 4, Po0.05)
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(Figure 1b and c). Incubation in the high-glucose medium
decreased eNOS dimerization (Figure 2a) and phosphoryla-
tion at Ser1179 (Figure 2b) without changing eNOS
monomer expression or phosphorylation at Thr479, whereas
incubation with mannitol as an osmolar control did not have
the same effects (Supplementary Figure S1a and b online).
HG also decreased NOS activity, indicated by decreased levels
of the stable end products of NO (nitrate/nitrite) (to
0.53±0.07 fold of NG. n¼ 4, Po0.05 compared with NG
or mannitol control) (Figure 2c and Supplementary Figure
S1c online).
Effects of sepiapterin and L-arginine on HG–induced GEnC
injury
We treated the GEnCs exposed to high-glucose medium with
the NO precursor, L-arginine, or the tetrahydrobiopterin
(BH4) cofactor, sepiapterin. Either L-arginine or sepiapterin
partially corrected the HG–induced defects in eNOS dimer-
ization and phosphorylation (Figure 2a and b), as well as
eNOS activity (to 0.86±0.05- and 0.83±0.08-fold control
by L-arginine or sepiapterin, respectively, n¼ 4, Po0.05
compared with untreated) (Figure 2c). In addition, both
L-arginine and sepiapterin significantly blunted GenC altera-
tions in permeability and apoptosis induced by incubation in
the high-glucose medium (Figure 1b–d).
eNOS dysfunction in db/db mice
db/db mice are a well-established type 2 diabetic model, but
some strains are relatively resistant to diabetic renal injury
despite the significant hyperglycemia.15,16 db/db mice on the
BKS background have been shown to develop hyperglycemia
and diabetic renal injury.17,18 We found that at 34 weeks, db/
db (BKS) mice had developed glomerulopathy characterized
by mesangial matrix accumulation (Figure 3a), foot process
effacement, and increased glomerular basement membrane
(GBM) thickness (154±6 in BKS control vs. 335±23 nm in
untreated db/db mice) (Figure 3a and b) and had significant
albuminuria (alb/cre: 18±3 in BKS control vs. 759±281 in
untreated db/db, n¼ 8, Po0.05) (Figure 3c) and hyperfiltra-
tion (glomerular filtration rate: 206±33 ml/min in BKS
control; 403±36 in untreated db/db, n¼ 6–12, Po0.05)
(Figure 3d). Furthermore, urine F2-isoprostanes, a marker of
oxidative stress, increased in the diabetic mice (5.7±0.9 in
db/db mice vs. 1.4±0.1 ng 8-iso-PGF2a/mg Cr in BKS
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Figure 1 |High glucose increased bovine serum albumin (BSA) permeability and apoptosis in glomerular endothelial cells (GEnCs);
these effects were inhibited by sepiapterin or L-arginine. (a) High glucose (HG), but not mannitol, increased permeability in GEnCs,
indicated by BSA clearance at 5–40min. *Po0.05 HG versus normal medium (NG) or osmolality control (mannitol at same concentration).
(b) Sepiapterin (Sep) and L-arginine (L-arg) attenuated HG increases in permeability, *Po0.05 HG versus normal medium or HG with Sep or
L-arg coincubation. (c) Effect of HG on apoptosis in GEnCs. Representative images of terminal transferase dUTP nick-end labeling (TUNEL)
assay from four independent experiments. (d) Sep and L-arg prevented HG-induced apoptosis. *Po0.05 HG versus normal medium or
HG with Sep or L-arg coincubation.
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control, n¼ 6–11, Po0.05) (Figure 3e). Increased oxidative
stress in db/db mice was also confirmed by the accumulation
of nitrotyrosine, another superoxide marker (Figure 3f).
To investigate the potential role of eNOS in the diabetic
renal injury, we determined glomerular eNOS expression.
There were no differences in eNOS monomer expression
between control and diabetic mice (Figure 4a), which was
further confirmed by immunohistochemical staining (data
not shown). However, glomerular eNOS dimerization
(Figure 4b) and phosphorylation at Ser1179 (Figure 4c)
decreased byB50% in db/db mice, whereas phosphorylation
at Thr497 was unchanged (Figure 4c). HG–mediated
alterations in endothelial function have been reported to be
associated with reduced intracellular BH4.
19,20 In agreement
with these findings, we found that glomerular BH4 in db/db
mice (0.7±0.1 ng/mg pro.) was significantly lower than BKS
control (2.3±0.2 ng/mg pro., n¼ 6, Po0.05).
Sepiaterin or L-arginine partially restored eNOS function and
attenuated renal injury in db/db mice
To examine the impact of L-arginine or sepiapterin in vivo, we
administered these agents to 26-week-old db/db mice for 8
weeks. Sepiapterin treatment significantly restored glomeru-
lar BH4 levels (to 1.9±0.3 ng/mg pro., n¼ 6, Po0.05
compared with untreated db/db). Consistent with the in
vitro results, both L-arginine and sepiapterin improved
glomerular eNOS function in db/db mice, indicated by
restoration of eNOS dimerization (Figure 4b) and phosphor-
ylation at Ser1179 (Figure 4c). In addition, oxidative stress,
indicated by nitrotyrosine accumulation and urinary F2-
isoprostane levels, was significantly decreased (3.1±0.2 ng
8-iso-PGF2a/mg Cr for L-arginine and 2.7±0.2 for sepiap-
terin, n¼ 6–11, Po0.05 compared with untreated) (Figure 3e
and f).
Neither L-arginine nor sepiapterin treatment markedly
affected the increased mesangial expansion, but both of
them reduced GBM thickness and foot-process effacement
in db/db mice (Figure 3a and b). They also significantly
reduced albuminuria (sepiapterin: 40±7 and L-arginine:
163±37mg alb/mg Cr, respectively, n¼ 6–8, Po0.05 vs. un-
treated db/db) (Figure 3c) without affecting glomerular filtration
rate (398±16 in sepiapterin and 425±50ml/min in L-arginine,
respectively, n¼ 6, Po0.05 compared with BKS control; not
significantly different vs. untreated db/db) (Figure 3d).
DISCUSSION
Our studies showed that HG induced dysfunction of GEnCs
in vitro, as indicated by the increased permeability to BSA
and apoptosis, as well as decreased eNOS dimerization,
impaired eNOS phosphorylation at Ser 1179, and decreased
NO production. All of these abnormalities were ameliorated
by coincubation with either the NO precursor, L-arginine, or
with sepiapterin, a stable precursor of the eNOS cofactor,
tetrahydrobiopterin. These in vitro findings were confirmed
in db/db (BKS) mice, in which supplementation with either
sepiapterin or L-arginine attenuated albuminuria and GBM
thickness and decreased oxidative stress.
NO has an important role in controlling vascular tone and
modulating platelet activation. Decreased NO bioactivity
contributes to arterial thrombosis and endothelial dysfunc-
tion.21 Chronic kidney diseases, including diabetic nephro-
pathy, are often characterized by relative NO deficiency,
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Figure 2 | Sepapterin (Sep) and L-arginine (L-arg) reversed high glucose–induced endothelial nitric oxide synthase (eNOS)
impairment in glomerular endothelial cells (GEnCs). (a) High glucose did not alter eNOS expression, but decreased eNOS dimerization in
GEnCs, which could be prevented by Sep or L-arg. Representative photo from three independent experiments. (b) High glucose decreased
eNOS phosphorylation at Ser1179, without significant change at Thr479. Sep or L-arg coincubation reversed phosphorylation at Ser1179.
Representative photo from three independent experiments. (c) High glucose reduced nitrate/nitrite production by GEnCs, which was
corrected by supplementation with Sep or L-arg. *Po0.05 compared with normal medium or high glucose with Sep or L-arg. HG, high
glucose; NG, normal glucose.
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which may contribute to disease progression.22 NO is
synthesized from L-arginine by its synthases. eNOS is the
major source of NO production in vascular endothelial cells,
including the endothelium of preglomerular vessels and
glomeruli.23
Accelerated glomerular injury in diabetic mice with eNOS
deficiency strongly suggests that deficient eNOS activity may
have an important role in the pathogenesis of diabetic
nephropathy,13,24,25 although there have been conflicting
results about eNOS regulation in the diabetic kidney, which
may relate to whether studies were conducted in early or
late injury.7–12,26 Previous studies in isolated blood vessels27,28
and cultured umbilical vein cells29,30 have been used as in vitro
systems to examine the role of eNOS on endothelial function.
Notably, GEnCs represent a microvascular endothelial cell
with unique characteristics31,32 and have a critical role in
the pathogenesis of diabetic nephropathy. In the current
study, we focused on the impact of hyperglycemia on
eNOS impairment in cultured mouse GEnCs. In cultured
GEnCs, we found that HG increased both permeability to
 BKS db/db  control db/db+Sep db/db+L-arg
400
300
200
100
0
400
1500
1000
500 8
6
4
2
0
500
300
200
*
*
#
*
#
100
00
Al
bu
m
in
 (μ
g)/
cre
ati
nin
e
 
(m
g)
G
FR
 (μ
l/m
in
)
Is
op
ro
st
an
e/
cr
ea
tin
in
e 
(ng
/m
g)
*
#
G
BM
 th
ick
ne
ss
 (n
m)
BK
S
db
/db
 co
ntr
ol
db
/db
+S
ep
db
/db
+L-
ar
g
BK
S
db
/db
 co
ntr
ol
db
/db
+S
ep
db
/db
+L-
ar
g
BK
S
db
/db
 co
ntr
ol
db
/db
+S
ep
db
/db
+L-
ar
g
BK
S
db
/db
 co
ntr
ol
db
/db
+S
ep
db
/db
+L-
ar
g
BKS db/db control db/db+Sep db/db+L-arg
Figure 3 | Sepiapterin (Sep) and L-arginine (L-arg) attenuated renal injury in db/db mice. (a) The upper panel indicates glomerular
mesangial expansion in db/db mice at 34 weeks by Periodic Acid Schiff staining, Bars: 20 mm; the lower panel indicates glomerular basement
membrane (GBM) thickness and foot process effacement (red arrow) in db/db mice with or without treatment with Sep/L-arg, bars: 2 mm.
(b) GBM thickness. *Po0.05, compared with wild-type BKS; #Po0.05, versus each treatment. (c) Sep or L-arg decreased albuminuria in
db/db mice at 34 weeks of age. *Po0.05, compared with wild-type BKS; #Po0.05, versus each treatment. (d) Sep or L-arg had no effect
on hyperfiltration seen in db/db mice, determined by fluorescein isothiocyanate-inulin clearance. *Po0.05, BKS versus db/db mice regardless
of treatments. (e) Sep or L-arg decreased elevations in urine isoprostane excretion in db/db mice. *Po0.05, compared with wild-type BKS;
#Po0.05, versus each treatment. (f) Increased nitrotyrosine accumulation in db/db mice was attenuated by Sep or L-arg treatment.
Representative photo from three independent experiments. GFR, glomerular filtration rate.
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BSA and apoptosis, in association with endothelial eNOS
dysfunction.
There is evidence that activation of eNOS requires
formation of a homodimer through a linkage between the
N-terminal oxygenase domains.33 Although we did not find
any significant alteration in eNOS monomer expression in
glomeruli from db/db mice at 34 weeks or in GEnCs in
response to HG, there was decreased eNOS dimerization.
We also found that in both diabetic glomeruli and high-
glucose GEnCs, eNOS phosphorylation was impaired at
Ser1179 without significant alteration at Thr497. A crucial
role for posttranslational control of eNOS bioactivity has been
suggested, owing to its long half-life at baseline (10–35 h).34,35
Akt-dependent phosphorylation of eNOS at Ser1179 is
essential for endothelium-dependent relaxation,36 whereas
phosphorylation at Thr497 is considered inhibitory.37
Reduced phosphorylation of eNOS at Ser1179 has previously
been reported in moderately hyperglycemic diabetic rats.38
In addition to decreased eNOS expression and decreased
eNOS activity due to uncoupling by reactive oxygen
species,22 alterations in the availability of substrate and/or
essential cofactors may lead to decreased NO production.
When either the essential substrate, L-arginine, or the
essential cofactor, BH4, is limited, electron transfer from
eNOS flavins becomes uncoupled from L-arginine oxidation,
and superoxide is produced from the oxygenase domain,39–41
which may further reduce NO bioactivity and increase oxida-
tive stress within endothelial cells by scavenging NO and
forming peroxynitrite.42 Reduced levels of both L-arginine
and BH4 have been observed in diabetic rats,
20,43 with more
profound depletion in endothelial cells than in plasma.20
Modulation of the arginine–NO pathway by supplementa-
tion with arginine may have protective effects on diabetic
rats44 and patients.20 In a previous study, administration
of BH4 to db/db mice did not affect glucose, triglyceride,
and cholesterol levels or body weight, but enhanced the
reactivity of small mesenteric arteries to phenylephrine.45
Acute intra-arterial infusion of BH4 leads to short-term
improvements of forearm blood flow responses to endothelium-
dependent vasodilators in patients with type 2 diabetes.46
Sepiapterin, the immediate precursor of BH4 via the biopterin
salvage pathway, is less sensitive to oxidative stress than BH4.
47
It is noteworthy that administration of either L-arginine or
sepiapterin not only corrected the defects in eNOS dimeriza-
tion and phosphorylation but also decreased oxidative stress
and partially corrected functional and structural glomerular
abnormalities. Previous studies have also reported beneficial
effects of L-arginine on renal dilatation in animal models48 and
humans.49 The current in vitro study provided evidence for
a direct role of both sepiapterin and arginine on GEnCs,
independent of vasodilation.
In summary, we found that providing either a precursor for
NO production or a stable precursor of tetrahydrobiopterin
significantly improved the function of cultured GEnCs and
decreased progression of glomerular injury in a model of type 2
diabetes. Recently, a more stable preparation of oral BH4,
sapropterin dihydrochloride (Kuvan, BioMarin, Tiburon, CA),
has been developed and approved by the Food and Drug
Administration for treatment of patients with phenylketo-
nuria.50 Our results provide evidence that BH4 supplementa-
tion may have therapeutic potential in diabetic nephropathy.
MATERIALS AND METHODS
Materials
Sepiapterin, eNOS polyclonal antiserum, and Nitrate/Nitrite Colori-
metric Assay Kits were from Cayman Chemical Co (Ann Arbor, MI).
Rabbit anti-phospho-serine-1179 eNOS (bovine) and anti-phospho-
Thr-497 polyclonal antibody were from Cell Signaling Technology
(Danvers, MA); anti-nitrotyrosine antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). The TUNEL (terminal transferase
dUTP nick-end labeling) apoptosis detection kit was from Upstate
(Lake Placid NY); other reagents were purchased from Sigma
Chemical (St Louis, MO).
Experimental animals
We used db/db mice on the nephropathy-susceptible BKS back-
ground51,52 as a model of type 2 diabetes. Age-matched (26 weeks old)
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Figure 4 | Sepiapterin (Sep) and L-arginine (L-arg) reversed endothelial nitric oxide synthase (eNOS) impairment in db/db mice.
(a) No significant differences in glomerular eNOS expression were detected between BKS and db/db mice with or without treatment.
(n¼ 4; NS). (b) There was decreased eNOS dimerization in glomeruli from db/db mice, which was corrected by administration of Sep or
L-arg (n¼ 4, *Po0.05, compared with wild-type or treated groups). (c) There was decreased eNOS phosphorylation at Ser1179, but not at
Thr479, in glomeruli from db/db mice and normalization by Sep/L-arg treatment. Representative photo was from three independent
experiments.
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male mice were divided into the following groups: (1) Wild type
(BKS); (2) db/db untreated (db/db control); (3) db/db mice treated
with sepiapterin, in which the mice were administered fresh
sepiapterin solution (10mg/kg/day by gavage) for 8 weeks (from
26 to 34 weeks); (4) db/db mice with L-arginine, in which L-arginine
(100mg/kg/day in the drinking water) was administered for the
same period. Mice were killed at the end of 34 weeks. All animal
procedures were approved by the Animal Care and Use Committee
of Vanderbilt University Medical Center.
Assessment of glomerular injury
Renal injury was assessed histologically with light microscopy by
hematoxylin and eosin, Periodic Acid Schiff, and Jones staining and
by electron microscopy. GBM thickness was randomly measured as
the distance between the endothelial cell and epithelial cell plasma
membranes  20 for each sample and evaluated by the renal
pathologist. Urinary albumin levels were determined by enzyme-
linked immunosorbent assay (ELISA) using a murine micro-
albuminuria ELISA kit, AlbuwellM (Exocell, Philadelphia, PA).
The urine creatinine concentration was measured with a microplate
assay kit, Creatinine Companion (Exocell). All measurements were
recorded in duplicate, and albuminuria was determined as the ratio
of urinary albumin (mg/ml) to creatinine (mg/ml). Renal function
was evaluated by glomerular filtration rate as described previously.13
F2-isoprostane assay
F2-isoprostanes were measured in urine using stable isotope dilution
methods and gas chromatography negative ion chemical ionization
mass spectrometry,53,54 and expressed as ng/mg urine creatinine.
Isolation of glomeruli
Glomeruli were isolated immediately after killing, using the
Dynabeads method modified from Takemoto et al.55 Briefly, mice
were anesthetized by an injection of nembutal (0.05mg/g BW) and
perfused through the descending aorta with 8 107 Dynabeads
diluted in phosphate-buffered saline. The kidneys were removed,
minced into 1-mm3 pieces, and digested in collagenase (1mg/ml
collagenase A, 100U/ml deoxyribonuclease I in Hank’s Balanced Salt
Solution (HBSS)) at 37 1C for 30min with gentle agitation. The
collagenase-digested tissue was gently pressed through a 100-mm cell
strainer using a flattened pestle, and the cell strainer was then
washed with 5ml of cold HBSS. The filtered cells were passed
through a new cell strainer without pressing and the cell strainer
washed with 5ml of cold HBSS. The cell suspension was then
centrifuged at 200 g for 5min at 4 1C. The supernatant was discarded
and the cell pellet was resuspended in 2ml of cold HBSS. Finally,
glomeruli containing Dynabeads were gathered by a magnetic
particle concentrator and washed three times with cold HBSS.
During the procedure, kidney tissues were kept at 4 1C, except for
the collagenase digestion, which was kept at 37 1C. The preparation
consisted of 490% glomeruli.
Cultured mouse GEnCs
We used early-passage GEnCs from Michael Madaio,56 grown in
DMEM/F12 medium with 10% FBS, at 37 1C in humidified air with
5% CO2. After quiescence for 16–24 h, subsets of cells were exposed
to high-glucose (30mM) medium or osmolality control medium
(30mM mannitol) for 48 h before experimentation. Subsets of cells
grown in high-glucose medium were coincubated with L-arginine
(3mM) or sepiapterin (100 mM).57
Immunoblotting
Cultured cells or isolated glomeruli were homogenized as described
previously.58 Proteins were resuspended in SDS sample buffer, diluted
in SDS buffer containing 2-mercaptoethanol (Sigma Chemical), and
boiled for 10min before loading. The samples were run on 8% sodium
dodecyl sulfate polyacrylamide gel electrophoresis gels under reducing
conditions and transferred onto polyvinylidene fluoride membrane
(Immobilion-P; Millipore, Bedford, MA). After blocking with 5%
nonfat milk in Tris-buffered saline, the membranes were exposed to
the primary antibody overnight at 4 1C, followed by horseradish
peroxidase–conjugated secondary antibodies. The horseradish perox-
idase signal was enhanced using the enhanced chemiluminescence
method, and the images were developed on high-performance
autoradiography film, Hyperfilm MP (Amersham Biosciences, Buck-
inghamshire, UK). Membranes were rehybridized with goat anti-b-
actin antibody (Santa Cruz Biotechnology) to normalize protein
loading. For detection of eNOS dimerization, we used nondenaturing,
low-temperature sodium dodecyl sulfate polyacrylamide gel electro-
phoresis to run gels with 50mg protein loading in each well without
boiling, and calculated eNOS dimer/monomer ratios.
Apoptosis detection
ATUNEL apoptosis detection kit (Upstate) was used for measurements.
Propidium iodide was used for counterstaining. The percentage of
apoptotic cells in 400 total cells from the same field was determined
for quantification.
Glomerular BH4 (tetrahydrobiopterin)
Glomerular BH4 was evaluated with the Tetrahydrobiopterin ELISA
Kit (MyBioSource, LLC, San Diego, CA) using the company’s
instructions. BH4 was normalized to protein content, expressing as
ng/mg pro.
Endothelial cell permeability
Permeability was detected by clearance of albumin across endo-
thelial monolayers as described previously.59,60 Briefly, monolayers
were grown to confluence on the inserts of Transwell (3.0 mm;
Becton Dickinson Labware, Franklin Lake, NJ, 8 105 cells/insert).
After washing, the monolayers were covered immediately with
HBSS containing a trypan blue–albumin complex (trypan blue
0.035% and BSA 0.8%) and incubated at 37 1C with continuous
agitation. Samples were collected every 5min from the bottom well
up to 40min and were replaced by an equal volume of HBSS.
Absorbance at 590 nm was measured from both the insert and the
lower well fluids. Results were expressed as clearance of BSA,
i.e., the amount of TB-BSA detected in the lower chamber, expressed
as a percentage of the total TB-BSA initially added to the upper
chamber.
NOS activity from cultured GEnCs
Activity was measured with a Nitrate/Nitrite Colorimetric Assay Kit
(Cayman Chemical) from stable end products of the reaction of NO
with molecular oxygen, according to the manufacturer’s instruc-
tions, normalized by the protein content and expressed as fold
control (cells gown in normal medium).
Statistical analyses
All values are presented as mean±s.e.m. ANOVA and Bonferroni
t-tests were used for statistical analysis, and differences were
considered significant when Po0.05.
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